Pandemic influenza A virus vaccines - CSL/NIAID

Drug Profile

Pandemic influenza A virus vaccines - CSL/NIAID

Alternative Names: Focetria (Mock-up); Foclivia; Influenza A virus H5N1/H9N2 subtypes vaccine - CSL/NIAID

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases; Novartis
  • Developer CSL
  • Class Influenza A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Influenza A virus infections

Most Recent Events

  • 13 Jan 2010 Interim immunogenicity data from a clinical study in patients with end-stage renal disease released by SciCLone and Sigma-Tau
  • 24 Jul 2009 CHMP of the EMEA recommends approval of Foclivia®, a vaccine from Novartis that is a duplicate of Focetria® and consists of H5N1 virus surface antigens, in the European Union
  • 08 May 2007 Registered as mock-up vaccine for Influenza A virus infections in European Union (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top